🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity ◆ Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing ◆ Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich ◆ Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery ◆ Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma ◆ Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide ◆ The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany ◆ Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact ◆ Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity ◆ Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing ◆ Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich ◆ Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery ◆ Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma ◆ Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide ◆ The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany ◆ Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact ◆
Clinical Trials in Canada / NCT07127523
Starting soon Not applicable

A Clinical Trial to Investigate the Efficacy and Safety of GenLabs' Social Renew on Improving Acne Symptoms and Skin Repair Among Healthy Adults

NCT07127523 · tracked via the Priya Life Science Canada tracker
Sponsor
GenCanna Acquisition Corp
Phase
Not applicable
Started
2026-07
Last updated
2026-06-30

Condition(s) studied

Acne

Investigational drug(s) / intervention(s)

Social RenewPlacebo

Social Renew: This group receives a cleanser, serum, and cream.

Placebo: This group receives a cleanser, serum, and cream.

Study summary

The goal of this interventional clinical trial is to investigate the efficacy and safety of GenLabs' Social Renew on improving acne symptoms and skin repair among healthy adults. The main question\[s\] it aims to answer is:

What is the difference in the change in acne symptoms as assessed by the Acne Quality of Life Questionnaire (ACNE-QoL) between GenLabs' Social Renew and placebo from baseline at Day 30.

Eligibility

Sex
ALL
Min age
18 Years
Max age
65 Years
Healthy volunteers
No
Inclusion Criteria: 1. Males and females between 18 and 65 years of age inclusive 2. Females not of child-bearing potential, defined as those who have undergone a sterilization procedure (e.g. hysterectomy, bilateral oophorectomy, bilateral tubal ligation, complete endometrial ablation) or have been post-menopausal for at least 1 year prior to screening Or, Individuals of child-bearing potential must self-report confirmation they are not pregnant, do not plan to become pregnant, and agree to use a medically approved method of birth control for the duration of the study. All hormonal birth control must have been in use for a minimum of three months. Acceptable methods of birth control include: * Hormonal contraceptives including oral contraceptives, hormone birth control patch (Ortho Evra), vaginal contraceptive ring (NuvaRing), injectable contraceptives (Depo-Provera, Lunelle), or hormone implant (Norplant System) * Double-barrier method * Intrauterine devices * Non-heterosexual lifestyle or agrees to use contraception if planning on changing to heterosexual partner(s) * Vasectomy of partner at least 6 months prior to screening * Abstinence 3. Experience acne on facial skin that is visible to the participant and is confirmed by the QI at screening and at baseline 4. Willingness to complete questionnaires and diaries associated with the study, to capture and upload photos, and to complete all virtual visits 5. Willingness to maintain the same skincare regimen throughout the study, including maintaining make-up routine without the addition of new make-up products 6. Agrees to maintain current lifestyle habits (diet, physical activity, medications, supplements, and sleep) as much as possible throughout the study 7. Provided voluntary, written, informed consent to participate in the study 8. Agrees to have de-identified photos of face available for marketing purposes 9. Self-reported healthy as determined by medical history with no unstable diagnosed medical conditions Exclusion Criteria: 1. Individuals who are pregnant, breast feeding, or planning to become pregnant during the study 2. Self-reported allergy, sensitivity or intolerance to investigational product or placebo ingredients, including allergy to salicylic acid or any form of salicylates, preventing topical use 3. Individuals with significant facial hair that would impede the visualization of facial acne and may interfere with the use of the product, such as beards and long sideburns, as assessed by the QI 4. Self-reported psoriasis, dermatitis, vitiligo, or any other active dermatological condition other than acne affecting the face 5. Self-reported use of topical products on the face marked with claims relating to skin health, or those with claims relating to acne during the study, except for noncomedogenic moisturizers and sunscreen 6. Self-reported shaving, waxing, tweezing, or threading of the face or use of nose/facial strips within 3 days prior to each photo capture 7. Procedures such as microdermabrasion, peels, acne treatments, filler, botulinum toxin, red light therapy, pore suction therapy, or laser on the face within three months of baseline 8. Self-reported UVA or UVB exposure to the face in the past two weeks or expected during the study to avoid sunburn. 9. Current use of prescribed and/or over-the-counter (OTC) medications, supplements, and/or consumption of food/drinks that may impact the efficacy and/or safety of the investigational product (Sections 7.3.1 and 7.3.2) 10. Self-reported asthma 11. Self-reported presence of a peptic ulcer 12. Self-reported autoimmune disease or are immune compromised 13. Self-reported ongoing and unstable diseases/conditions in the past three months, including: 1. Arthritis and joint diseases 2. Gastrointestinal diseases 3. Hypertension 4. Type I or type II diabetes 5. Cardiovascular disease 6. Kidney diseases 7. Liver diseases 8. Thyroid condition 9. Psychiatric conditions 14. Major surgery in the past 3 months or individuals who have planned surgery during the course of the study 15. Cancer, except skin basal cell carcinoma completely excised with no chemotherapy or radiation with a follow up that is negative. Volunteers with cancer in full remission for more than five years after diagnosis are acceptable 16. Alcohol intake average of \>2 standard drinks per day 17. Alcohol or drug abuse within the last 12 months 18. Participation in other clinical research studies 30 days prior to screening 19. Individuals who are unable to give informed consent 20. Any other condition or lifestyle factor that may adversely affect the participant's ability to complete the study or its measures or pose significant risk to the participant

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
KGK Science Inc. London Ontario

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07127523 on ClinicalTrials.gov ↗ ← All trials in Canada